The molecular division of DiaSorin has added to its infectious disease portfolio with the launch of Iam Toxo.

Toxoplasmosis (Toxo) infection can have severe or fatal consequences for immunocompromised/deficient patients (such as HIV, AIDS, cancer and transplant patients) where infection can result in complications including encephalitis, pulmonary disease and hepatitis¹ and Toxo encephalitis (TE) is a frequent cause of death in AIDS patients².  While serological analysis is widely used for diagnosis of Toxo in immunocompetent individuals, molecular methods are necessary for diagnosis in immunocompromised patients.   

“Iam Toxo rapidly confirms Toxo infection. The diagnostic sensitivity of the assayhas been proven to be equivalent to PCR but delivers results produced in a fraction of the time that PCR requires”, said Paul Eros, Global Vice President Molecular, DiaSorin.  “This assay is the latest addition to the unique and rapidly expanding DiaSorin Q-LAMP assay portfolio for our Liaison^® Iam molecular instrument, an easy-to-use benchtop device which provides laboratories with a cost-effective, scaleable, molecular diagnostic solution.  This is a perfect solution for use in laboratory facilities of all sizes, including those that are located close to the patient.”  

“People should not confuse DiaSorin Q-LAMP with conventional LAMP technology.  DiaSorin Q-LAMP assays provide many advantages.  They are rapid, real-time, fluorescent, quantitative/qualitative assays designed to be used for multiplexed applications, enabling amplification and detection of multiple targets in a single reaction.  Iam Toxo is a duplex fluorescent Q-LAMP assay employing primers designed to recognise a multi-copy repeat region of the Toxoplasma gondii genome, common to all clinically-relevant subtypes.” Eros concluded. 

The Iam Toxo assay, when used with the Liaison Iam instrument, can be used for the detection of all clinically-relevant subtypes of T. Gondii in human plasma, CSF and amniotic fluid.  In addition to being used for the primary detection of infection in immunocompromised/deficient patients, Iam Toxo is used as a secondary high sensitivity confirmation (after serological testing) for the diagnosis of Toxo infection in pregnant women and of congenital toxoplasmosis in infants.  Iam Toxo is CE-IVD validated for use outside of the USA and Canada only. For more information about Iam Toxo and the DiaSorin infectious disease portfolio of molecular diagnostics assays (including Parvovirus B19, BK virus and Varicella zoster virus) for the Liaison Iam instrument.

more about Iam Toxo

more about Diasorin